Parameter Identifiability of Fundamental Pharmacodynamic Models

Issues of parameter identifiability of routinely used pharmacodynamics models are considered in this paper. The structural identifiability of 16 commonly applied pharmacodynamic model structures was analyzed analytically, using the input-output approach. Both fixed-effects versions (non-population, no between-subject variability) and mixed-effects versions (population, including between-subject variability) of each model structure were analyzed. All models were found to be structurally globally identifiable under conditions of fixing either one of two particular parameters. Furthermore, an example was constructed to illustrate the importance of sufficient data quality and show that structural identifiability is a prerequisite, but not a guarantee, for successful parameter estimation and practical parameter identifiability. This analysis was performed by generating artificial data of varying quality to a structurally identifiable model with known true parameter values, followed by re-estimation of the parameter values. In addition, to show the benefit of including structural identifiability as part of model development, a case study was performed applying an unidentifiable model to real experimental data. This case study shows how performing such an analysis prior to parameter estimation can improve the parameter estimation process and model performance. Finally, an unidentifiable model was fitted to simulated data using multiple initial parameter values, resulting in highly different estimated uncertainties. This example shows that although the standard errors of the parameter estimates often indicate a structural identifiability issue, reasonably “good” standard errors may sometimes mask unidentifiability issues.

[1]  R. Bellman,et al.  On structural identifiability , 1970 .

[2]  Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix Computations , 2016, The AAPS Journal.

[3]  Donald E. Mager,et al.  General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[4]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.

[5]  M. J. Chapman,et al.  A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan. , 2004, Mathematical biosciences.

[6]  The Input-Output Relationship Approach to Structural Identifiability Analysis , 2010 .

[7]  M J Chappell,et al.  Structural identifiability of models characterizing saturable binding: comparison of pseudo-steady-state and non-pseudo-steady-state model formulations. , 1996, Mathematical biosciences.

[8]  Meindert Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. , 2007, Annual review of pharmacology and toxicology.

[9]  Johan Gabrielsson,et al.  Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[10]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[11]  M. Chappell,et al.  PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data. , 2016, Journal of pharmacological and toxicological methods.

[12]  S. Visser,et al.  Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human. , 2013, Journal of pharmacological and toxicological methods.

[13]  Michael Rowley,et al.  Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. , 2011, Current topics in medicinal chemistry.

[14]  Johan Karlsson,et al.  An Efficient Method for Structural Identifiability Analysis of Large Dynamic Systems , 2012 .

[15]  Neil D. Evans,et al.  Structural identifiability of surface binding reactions involving heterogeneous analyte: Application to surface plasmon resonance experiments , 2013, Autom..

[16]  Keith R. Godfrey,et al.  An Identifiability Analysis of a Parent–Metabolite Pharmacokinetic Model for Ivabradine , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  Meindert Danhof,et al.  Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. , 2009, Drug metabolism and pharmacokinetics.

[18]  M. Gastonguay,et al.  A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations , 2015, The AAPS Journal.

[19]  Ursula Klingmüller,et al.  Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood , 2009, Bioinform..

[20]  Arthur A M Wilde,et al.  Cardiac ion channels in health and disease. , 2010, Heart rhythm.

[21]  James W. T. Yates,et al.  The design and analysis of parallel experiments to produce structurally identifiable models , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[22]  Leif Carlsson,et al.  Assessment of the Ion Channel-blocking Profile of the Novel Combined Ion Channel Blocker AZD1305 and Its Proarrhythmic Potential Versus Dofetilide in the Methoxamine-sensitized Rabbit In Vivo , 2009, Journal of cardiovascular pharmacology.

[23]  D. Jonker,et al.  A Pharmacokinetic‐pharmacodynamic Model for the Quantitative Prediction of Dofetilide Clinical QT Prolongation from Human Ether‐a‐go‐go‐related Gene Current Inhibition Data , 2005, Clinical pharmacology and therapeutics.

[24]  J. Valentin,et al.  An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk , 2010, British journal of pharmacology.

[25]  O Della Pasqua,et al.  Assessing the Probability of Drug‐Induced QTc‐Interval Prolongation During Clinical Drug Development , 2011, Clinical pharmacology and therapeutics.

[26]  Johan Karlsson,et al.  Comparison of approaches for parameter identifiability analysis of biological systems , 2014, Bioinform..